| the hyperactivity-impul… | 0.29 |
| acceptable level | 0.24 |
| range | 0.57 |
| meet criterion | 0.57 |
| vary to person | 0.55 |
| become apparent | 0.55 |
| appear after exposure | 0.54 |
| indicate need | 0.53 |
| change over time | 0.53 |
| vary | 0.52 |
| develop after birth | 0.52 |
| develop including abdom… | 0.50 |
| More » |
| significant distress | 0.47 |
| impairment | 0.41 |
| dysfunction | 0.18 |
| negative impact | 0.33 |
| immediate medical atten… | 0.38 |
| treatment | 0.28 |
| medical attention | 0.23 |
| emergency care | 0.22 |
| supplemental systemic c… | 0.22 |
| surgery | 0.18 |
| mild | 0.70 |
| milder | 0.61 |
| severe | 0.58 |
| less severe | 0.57 |
| absent | 0.56 |
| apparent | 0.56 |
| significant | 0.56 |
| temporary | 0.55 |
| important | 0.55 |
| intermittent | 0.54 |
| More » |
| death | 0.42 |
| problem | 0.35 |
| hospitalization | 0.24 |
| discussed | 0.63 |
| associated with autism | 0.62 |
| treated | 0.61 |
| controlled | 0.61 |
| addressed | 0.60 |
| associated with the dis… | 0.58 |
| evaluated | 0.56 |
| managed | 0.56 |
| experienced by patient | 0.56 |
| reduced | 0.56 |
| More » |
| trauma | 0.48 |
| stress | 0.36 |
| celiac disease | 0.30 |
| aspartame use | 0.25 |
| extended periods of com… | 0.24 |
| problem | 0.23 |
| organ | 0.18 |
| esophageal dysfunction | 0.16 |
| flu | 0.31 |
| sinusitis | 0.29 |
| the symptoms of mercury… | 0.18 |